Issue link: http://clhia.uberflip.com/i/406567
35 APPENDIX LIST OF CLHIA RECOMMENDATIONS A. ENSURING SAFETY AND ENCOURAGING INNOVATION 1. The CLHIA recommends that where appropriate, clinical trials in Canada be head-to- head trials between the new drug and existing drugs or drug therapies. 2. The CLHIA recommends that Health Canada speed up access to new drugs by entering into bilateral agreements to recognize approvals in other select jurisdictions, such as the U.S. or Europe, that have processes similar to Canada's without impacting patient outcomes. 3. The CLHIA recommends that Health Canada establish a new, robust post-market surveillance of prescription drugs and that in doing so, Health Canada leverage lessons learned from international experience. 4. The CLHIA recommends that Health Canada implement a governance and monitoring framework for off-label prescribing that focuses on the health implications for Canadians as well as the implications for the financial sustainability of drug coverage in Canada. B. ENSURING AVAILABILITY OF COST EFFECTIVE PRESCRIPTION DRUGS 5. The CLHIA recommends that: • the mandate of the PMPRB be changed such that its goal is to achieve the lowest possible prices for Canadians, leveraging an economic and market driven